Stockscreener 앱 받기
15.87
0.79%
0.1247
전일 마감가:
$15.75
열려 있는:
$15.78
하루 거래량:
68,852
Relative Volume:
0.34
시가총액:
$616.47M
수익:
$25.42M
순이익/손실:
$-143.75M
주가수익비율:
-4.5737
EPS:
-3.4709
순현금흐름:
$-129.55M
1주 성능:
+24.80%
1개월 성능:
+14.37%
6개월 성능:
+128.40%
1년 성능:
+90.57%
1일 변동 폭
$15.00
$16.11
1주일 범위
$12.56
$16.19
52주 변동 폭
$4.93
$16.19
Entrada Therapeutics Inc Stock (TRDA) Company Profile
명칭
Entrada Therapeutics Inc
전화
857-305-1825
주소
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
15.88 | 611.42M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
425.06 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.63 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.16 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.47 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.76 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-11 | 개시 | Guggenheim | Buy |
| 2026-01-28 | 개시 | Oppenheimer | Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-01-05 | 개시 | Oppenheimer | Outperform |
| 2023-04-03 | 개시 | H.C. Wainwright | Buy |
모두보기
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance
Entrada Therapeutics president & COO sells $229,953 in shares By Investing.com - Investing.com Canada
Entrada Therapeutics president & COO sells $229,953 in shares - Investing.com
Entrada Therapeutics (TRDA) R&D president sells 25,907 shares under 10b5-1 plan - Stock Titan
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics R&D president sells $398,809 in shares By Investing.com - Investing.com UK
Entrada Therapeutics R&D president sells $398,809 in shares - Investing.com
Morgan Stanley Smith Barney files TRDA Form 144; 15,000 shares sold (TRDA) - Stock Titan
TRDA (NASDAQ: TRDA) reports 25,907 RSUs to sell; insider sold March 2026 - Stock Titan
Entrada Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month HighWhat's Next? - MarketBeat
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday - MarketBeat
Is Entrada Therapeutics (TRDA) stock showing strong momentum | Q4 2025: EPS Tops ViewsTrending Social Stocks - Newser
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Entrada Therapeutics (NASDAQ: TRDA) details 2026 proxy and equity plan changes - Stock Titan
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
TRDA (Entrada Therapeutics) reports narrower Q4 2025 loss than expected, shares edge lower on steep revenue decline.Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a Potential 52.97% Upside in the Biotech Sector - DirectorsTalk Interviews
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week HighShould You Buy? - MarketBeat
Sell Signal: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Buyback Activity & Long-Term Safe Investment Plans - baoquankhu1.vn
How Entrada Therapeutics Inc. (TRDA) Affects Rotational Strategy Timing - Stock Traders Daily
Entrada Therapeutics, Inc. $TRDA Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat
Investment Report: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
TRDA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Investor Mood: Does Entrada Therapeutics Inc have declining or rising EPS2026 AllTime Highs & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Entrada Therapeutics : Corporate Presentation April 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says - marketscreener.com
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - marketscreener.com
Is Entrada Therapeutics (TRDA) Stock Undervalued Now | Price at $13.32, Up 1.32%Fundamentals - Newser
TRDA PE Ratio & Valuation, Is TRDA Overvalued - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock - marketbeat.com
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Thera - GuruFocus
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com - Investing.com Canada
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock - Investing.com
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
(TRDA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TRDA (NASDAQ: TRDA) insider 10b5‑1 sales listed, 11,388-share trade noted - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-03-31 23:31:11 - baoquankhu1.vn
Risk Analysis: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc still a buy after recent gains2026 Retail & Capital Efficient Trade Techniques - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring a 65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Big Picture: Can Entrada Therapeutics Inc deliver consistent EPS growthTrade Analysis Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
Entrada Therapeutics Inc (TRDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
3.01%
자본화:
|
볼륨(24시간):